Related Experiment Video

Updated: Jun 21, 2026

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation
08:30

Glaucoma-inducing Procedure in an In Vivo Rat Model and Whole-mount Retina Preparation

Published on: March 12, 2016

Neuroprotective effects of angiotensin II type 1 receptor blocker in a rat model of chronic glaucoma

Hongwei Yang1, Kazuyuki Hirooka, Kouki Fukuda

  • 1Department of Ophthalmology, Kagawa University Faculty of Medicine, Kagawa, Japan.

Investigative Ophthalmology & Visual Science
|July 18, 2009
PubMed
Abstract

Insights

Candesartan, an AT1-R blocker, demonstrated significant neuroprotection in a rat glaucoma model. Treatment preserved retinal ganglion cells (RGCs) despite elevated intraocular pressure (IOP).

Area of Science:

  • Ophthalmology
  • Neuroscience
  • Pharmacology

Background:

  • Glaucoma is characterized by elevated intraocular pressure (IOP) leading to retinal ganglion cell (RGC) neurotoxicity.
  • Angiotensin II type 1 receptor (AT1-R) is implicated in ocular pathologies.
  • RGC survival is critical for vision preservation in glaucoma.

Purpose of the Study:

  • To evaluate the neuroprotective potential of candesartan, an AT1-R blocker, against RGC damage in a rat model of glaucoma.
  • To assess the impact of candesartan on RGC survival and AT1-R expression in glaucomatous eyes.

Main Methods:

  • A rat model of chronic glaucoma was established by cauterizing episcleral vessels, inducing a 2.5-fold IOP increase.
  • Rats received oral candesartan (1 mg/kg/d) or vehicle for 10 weeks.
  • RGC survival was quantified using immunohistochemistry, and AT1-R localization was examined.

Main Results:

  • Candesartan treatment did not alter systemic blood pressure.
  • RGC survival in candesartan-treated eyes (84.2% +/- 4.9%) was significantly higher than in untreated eyes (46.5% +/- 19.4%) (P < 0.05).
  • AT1-R expression was observed in retinal vessels and RGCs, with a notable increase in RGCs in candesartan-treated rats.

Conclusions:

  • Continuous candesartan treatment provides significant neuroprotection against RGC loss in a rat chronic glaucoma model.
  • Targeting the AT1-R pathway with candesartan may be a viable therapeutic strategy for glaucoma management.

More Related Videos

Laser-Induced Chronic Ocular Hypertension Model on SD Rats06:34

Laser-Induced Chronic Ocular Hypertension Model on SD Rats

Published on: December 4, 2007

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...